Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of ... from Period 1 baseline in adjusted Inflammatory Neuropathy Cause and Treatment ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis ... (SLE), idiopathic inflammatory myopathies (IIMs), haemolytic disease of ...

VYVGART is approved for generalized myasthenia gravis (gMG) and immune thrombocytopenia (Japan only). VYVGART Hytrulo is approved for gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).

Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete with rivals in ...

for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating ...

The final months of 2024 saw Nkarta launch two trials of NKX019: in lupus nephritis as well as in in systemic sclerosis, idiopathic inflammatory myopathy ... another in myasthenia gravis has ...

Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) score from baseline, were re-randomized 1:1:1 to batoclimab (340mg weekly ...

Responders to batoclimab in Period 1, defined as ≥2-point improvement in Myasthenia Gravis Activities of ... from Period 1 baseline in adjusted Inflammatory Neuropathy Cause and Treatment ...